Eledon pharmaceuticals appoints jan hillson, m.d., to its board of directors

Irvine, calif., july 02, 2021 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (als), today announced the appointment of jan hillson, m.d., to the company's board of directors. dr. hillson currently serves as senior vice president of clinical development at alpine immune sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases.
ELDN Ratings Summary
ELDN Quant Ranking